Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Central Europe Online .
Press releases published on May 6, 2025
Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress
GlobeNewswire
·
May 6, 2025
- Favorable clinical data in PD-(L)1 resistant patients - - Dose expansion enrollment complete with full data expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. …
CorMedix Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 6, 2025
‒ Q1 2025 Net Revenue of $39.1mm; Adjusted EBITDA of $23.6mm ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time BERKELEY HEIGHTS, NJ., May 06, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on …
Sono Hits the Road: Confirmed Trade Show Appearances Across Europe in 2025
GlobeNewswire
·
May 6, 2025
Munich, Germany, May 06, 2025 (GLOBE NEWSWIRE) -- The solar technology company Sono Group N.V. (OTCQB: SEVCF) (hereafter referred to as “Sono Group” or “Sono”, parent company to Sono Motors GmbH or “Sono Motors”) is pleased to announce its confirmed …
Neuronetics Reports First Quarter 2025 Financial and Operating Results
GlobeNewswire
·
May 6, 2025
MALVERN, Pa., May 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of …
Sanofi: Investing in prevention builds Europe’s health and competitiveness
GlobeNewswire
·
May 6, 2025
WARSAW, Poland, May 06, 2025 (GLOBE NEWSWIRE) -- As the Polish Presidency of the EU Council enters its final stage health policy remains central to Europe’s strategic agenda. At the European Economic Congress in Katowice, discussions reflected both the …
Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025
GlobeNewswire
·
May 6, 2025
PRINCETON, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody- …
Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer
GlobeNewswire
·
May 6, 2025
Cost-saving initiatives expected to extend company’s cash runway and support current operating plan commitments into mid-2026 Company to host conference call at 8:00 a.m. ET on May 15 to discuss business updates and first quarter 2025 financial results …
Topas Therapeutics’ TPM502 Achieves Gluten-specific Tolerance Induction, Positive Safety Profile in Phase 2a Trial in Celiac Disease Patients
GlobeNewswire
·
May 6, 2025
TPM502 achieved significant and dose-dependent reduction in IL-2 and IFN-γ release by gluten-specific T cells and durable immunomodulation of gluten-specific CD4+ T cells Patient-reported outcomes indicated dose-dependent reduction of symptoms following a …
Optima Health to acquire Care first
GlobeNewswire
·
May 6, 2025
Optima Health to acquire Care first, a leading provider of mental health services, for a net consideration of £15,000, adding c.£3.7 million revenue to the Group Acquisition provides Optima with increased scale in its Mental Health division and will …
Sitryx nominates SIT-047, a novel, oral MTHFD2 inhibitor, for clinical development in psoriatic arthritis
GlobeNewswire
·
May 6, 2025
Novel, oral candidate with first-in-class potential progresses to regulatory non-clinical studies to support a Clinical Trial Authorisation First indication will be psoriatic arthritis, a multi-billion dollar market opportunity, with potential across …
EnteroBiotix Presents Positive IBS-C Data at Digestive Disease Week® 2025
GlobeNewswire
·
May 6, 2025
EnteroBiotix Presents Positive IBS-C Data at Digestive Disease Week® 2025 EBX-102-02 was well tolerated and demonstrated clinically meaningful improvements across multiple symptom domains in IBS-C patients Ph2b trial in IBS-C initiating in H2 2025 to …
Iterum Therapeutics to Report First Quarter 2025 Financial Results on May 13, 2025
GlobeNewswire
·
May 6, 2025
DUBLIN, Ireland and CHICAGO, May 06, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both …
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
GlobeNewswire
·
May 6, 2025
WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will participate in the following May investor conferences: BofA Securities 2025 Healthcare Conference: Fireside chat on Tuesday, …
Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis
GlobeNewswire
·
May 6, 2025
Meaningful Fatigue score reduction seen in study is a critically important quality of life (QoL) measure for Multiple Sclerosis patients. All patients experienced stabilization of Expanded Disability Status Scale (EDSS) scores. TSPO-PET imaging showed …
ANOTHER STRONG START TO THE YEAR SUSTAINED BY PRODUCT MIX
GlobeNewswire
·
May 6, 2025
Net revenues of Euro 1,791 million, up 13.0% versus prior year, with total shipments of 3,593 units Operating profit (EBIT)(1) of Euro 542 million, up 22.7% versus prior year, with Operating profit (EBIT) margin of 30.3% Net profit of Euro 412 million and …
PKP S.A.’s President: “Without cheap electricity, rail cannot compete with other modes of transportation.”
GlobeNewswire
·
May 6, 2025
WARSAW, Poland, May 06, 2025 (GLOBE NEWSWIRE) -- “Thirty years ago, people travelled by rail because they had to. Today, they travel by rail because they want to. In order for people to consider rail their first choice for travel, it must be more …
Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025
GlobeNewswire
·
May 6, 2025
Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dual inhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona” or the “Company”), a …
CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN. BHD. ITS WHOLLY-OWNED SUBSIDIARY TO ACCELERATE GROWTH AND STOCKHOLDER VALUE
GlobeNewswire
·
May 6, 2025
KUALA LUMPUR, MALAYSIA, May 06, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”) today announced that it entered into an Exchange Agreement with FITTERS Diversified Berhad (9318.KL; “FITTERS …
First Atlantic Nickel Receives Junior Exploration Assistance Grant from Province of Newfoundland and Labrador
GlobeNewswire
·
May 6, 2025
VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- First Atlantic Nickel Corp. (TSXV: FAN) (OTCQB: FANCF) (FSE: P21) ("First Atlantic" or the "Company") expresses its gratitude to the Province of Newfoundland …
The 4 Best Male Enhancement Pills to Buy OTC, In Stores & Online 2025: Top Sex Pills for Men's Sexual Performance Over the Counter - Leading Edge Health
GlobeNewswire
·
May 6, 2025
Limassol, Cyprus, May 06, 2025 (GLOBE NEWSWIRE) -- The top male enhancement pills for 2025 is presented by Leading Edge Health Finding the best male enhancement pill can feel overwhelming with so many options available over the counter, in stores, and …